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Objective. To evaluate the impact of oxidative stress on vascular reactivity to vasoconstrictors and on nitric oxide (NO)
bioavailability in saphenous vein (SV) graft with endothelial dysfunction from hypertensive patients (HT). Methods. Endothelial
function, vascular reactivity, oxidative state, nitrites and NO release were studied in isolated SV rings from HT and normotensive
patients(NT).Onlyringswithendothelialdysfunctionwereused. Results.HTringspresentedahyperreactivitytovasoconstrictors
that was reverted by diphenylene iodonium (DPI). In NT, no eﬀect of DPI was obtained, but Nω-nitro-L-arginine methyl ester (L-
NAME) increased the contractile response. NO was present in SV rings without endothelial function. Nitrites were higher in
NT than in HT (1066.1 ± 86.3pmol/mg; n = 11 versus 487.8 ± 51.6; n = 23; P<0.01) and inhibited by nNOS inhibitor. L-
arginine reversed this eﬀect. Antioxidant agents increased nitrites and NO contents only in HT. The anti-nNOS-stained area by
immunohistochemistry was higher in NT than HT. HT showed an elevation of oxidative state. Conclusions. Extraendothelial NO
counter-regulates contractility in SV. However, this action could be altered in hypertensive situations by an increased oxidative
stress or a decreased ability of nNOS to produce NO. Further studies should be performed to evaluate the implication of these
results in graft patency rates.
1.Introduction
In coronary artery bypass grafting surgery (CABGS), the
vessels that must be used are internal mammary arteries
(IMA) and saphenous veins (SV); however, SVs present a
greater risk of occlusion [1]. Nitric oxide (NO) could be
involved in the improvement of SV graft patency rates [2, 3]
since NO plays a pivotal role in vascular homeostasis [4–6].
Three isoforms of NO synthase (NOS) exist: neural (nNOS),
inducible (iNOS), and endothelial (eNOS) [7]. Although
nNOS was ﬁrst described in neurons, it is also present in
vascular smooth muscle cell (VSMC) [8]. We have shown in
IMAthatextraendothelialNOisreleasedfromnNOSpresent
in VSMC [9, 10].
Oxidative stress plays a role in NO bioavailability [11].
Some studies have reported that superoxide (O2
−)c o n -
tributes to the development of hypertension [12, 13]. In
experimental hypertension, Li et al. [14] have found elevated
O2
− levels in veins, suggesting that NADPH oxidase activity
induces hyperreactivity to vasoconstrictors. In agreement
with these data, we have observed that enhanced NADPH
oxidase activity drives O2
− production in genetically hyper-
tensive rats [15]. In human IMA, we found that extraen-
dothelial NO counter-regulates angiotensin II (Ang II)
contractility and that this action is altered in hypertension,
probably by an increased oxidative stress and a decreased
nNOS ability to produce NO [9, 10]. In addition, in human
umbilical endothelial cells, NADH-/NADPH-oxidases play a
role in O2
− induced by Ang II [16]. In SV, antioxidant agents
improve endothelial function [17].
Alterations of the vascular reactivity, NO bioavailability,
andoxidativestresscouldaﬀectSVpatencyrates.Thisnotion
would be supported by some reports that indicated that
functional and structural abnormalities of SV result in graft
thrombosis, intimal hyperplasia, and occlusion [3, 18].2 International Journal of Hypertension
Table 1: Clinical proﬁle of the 44 study patients.
HT (n = 30) NT (n = 14)
Age, years 64 ±26 1 ±4
Sex, male/female 22/8 13/1
Body mass index 26.7 ± 0.6 25.4 ± 0.9
Systolic/diastolic blood pressure at the time of the hospitalization (mmHg) 122.9 ± 2/78.9 ± 2 116.7 ± 4/73.6 ± 4
Exsmokers, n (%) 14 (47) 9 (64)
Antecedents of dyslipidemia, n (%) 17 (57) 5 (36)
To the best of our knowledge, despite the fact that
hypertension is a major risk factor for coronary disease, the
impact of hypertension and the role of oxidative stress in the
contractile function of SV grafts have not been studied.
The objective of this work was to evaluate the impact
of oxidative stress on Ang II and norepinephrine-(NE-)
mediated vascular reactivity and NO bioavailability in SV
grafts of hypertensive patients (HT).
2.MaterialsandMethods
Discarded SV segments were obtained from CABGS (Centro
Modelo de Cardiolog´ ıa, Tucum´ an, Argentina). To establish
the impact of hypertension on oxidative stress, NO contents
and vascular contractility and strict inclusion criteria in
relation to the risk factors were taken into account. Patients
with diabetes, renal failure, pulmonary disease, peripheral
vascular disease in a clinical report, uncontrolled dyslipemia,
or active smoking at the time of surgery were not included.
To test the inﬂuence of hypertension, patients were divided
into two groups, hypertensive (HT) and normotensive (NT),
according to clinical report. The clinical characteristics are
shown in Table 1. Blood pressure was controlled at the
time of CABGS. Informed consent according to institutional
guidelines was obtained from each patient.
2.1. Vessel Preparation. After surgery, SVs were immediately
placed in Krebs solution (mM: NaCl 118.3; KCl 4.7; CaCl2
2.5; MgSO4 1.2; KH2PO4 1.2; NaHCO3 25; Glucose 11.1;
Na2EDTA 0.026), maintained at 4◦C, and transferred to the
laboratory. Each vessel was dissected free from connective
tissue, and 2 to 5 rings (5mm) were obtained.
2.2. Isometric Tension Measurement. Rings were mounted
between two stainless-steel wires in organ chambers ﬁlled
with Krebs solution, which had been gassed with 95% O2
and5% CO2 (pH 7.4).One wirewasanchored, andthe other
one was connected to an isometric force transducer (Gould
UC2,USA)andarecorder(KippandZonenBD41,Holland).
Isometric tension was measured under an initial tension of
3g, which was found to be the optimal tension in which the
depolarizing high K+ solution induced contraction [19]. All
preparations were equilibrated and washed every 15 minutes
during 120 minutes.
To evaluate endothelial function, a cumulative dose
response curve (CDRC) to acetylcholine (Ach) (10−8–
10−4 M) in precontracted NE (10−6 M) rings was performed.
Endothelial function was considered to be present when
rings relaxed in response to Ach. Similar Ach responses
were observed in all rings from the same patient, which
is necessary to point out. The absence of endothelium-
dependent relaxation was observed in rings from 86.4%
of the patients (NT: 12; HT: 26 patients). According to
the objectives of the present work, only these rings (n =
38) were used. In this regard, to rule out the presence of
endothelium,immunohistochemicalstudieswereperformed
(see below). To test endothelium-independent relaxation,
sodium nitroprusside (SNP) 10−5 M was added to NE-
precontracted rings. In all cases, SNP induced a nearly
complete relaxation (HT: 99 ± 6% and NT: 107 ± 11% of
NE pre-contraction; P:N S ) .
2.3. Reactivity to Ang II and NE. Ang II CDRC (10−10–
10−5 M) or NE CDRC (10−9–10−5 M) were performed. The
maximal contractile response (Rmax) and negative log of the
molar concentration inducing 50% of the Rmax (pEC50)w e r e
measured from the corresponding CDRC.
To evaluate the eﬀect of NO-mediated inhibition on Ang
II and NE reactivity, rings were pretreated with Nω-nitro-L-
arginine methyl ester (L-NAME: 10−4 M) for 30min.
Toevaluatethepossibleroleofoxidativestressinvascular
reactivity, rings were pretreated with diphenylene iodonium
(DPI: 10−5 M) or tempol (10−4 M) for 30min.
At the end of the experiments, vascular reactivity was
checked with 100mM KCl. Data with respect to tension were
presented in milligrams (mg).
2.4. Calculation of Nitrites. Nitrites were measured by the
Griess reaction, which is frequently used to indirectly
measure NO contents [20]. We have previously shown that
stretching is an ideal condition for in vitro nitrite dosage
in isolated human vessels [9, 10]. Therefore, simultaneous
in vitro measurements of vascular reactivity and nitrite
release were performed under 3g of preload. The absorbance
was measured spectrophotometrically at 540nm. Data with
respect to tissue were expressed in pmol/mg of tissue.
To corroborate an extraendothelial NO presence, some
rings were rubbed. The possible NOS isoforms involved
were evaluated by treatment with L-NAME 10−4 M, L-
NAME plus L-arginine 10−2 M, S-methyl-L-thiocitrulline
10−5 M(nNOSinhibitor),oraminoguanidine10−4 M(iNOS
inhibitor). Because constitutive NOS has been described
as a Ca2+/calmodulin-dependent enzyme, some rings wereInternational Journal of Hypertension 3
incubated in Ca2+-free media (Krebs solution without CaCl2
plus EGTA 3mM).
The role of oxidative stress on nitrite contents was
evaluated with DPI 10−5 Mo rt e m p o l1 0 −4 M.
2.5. Direct Measurement of NO. NO release was evaluated in
real time, with the membrane-type NO-sensitive electrode
(ISO-NOP; WPI, USA). This electrode records an electrical
current that is directly proportional to the NO concentration
[21]. The signal was acquired by the Apollo 4000 recording
system (WPI, USA). After 120 minutes of equilibration,
the electrode was stabilized and the baseline of the current
became stable. Data were expressed in nanoAmpers (nA).
The role of oxidative stress in the NO content was
evaluated with tempol 10−4 M.
2.6. Histological Studies. At the end of the experiments, the
r i n g sw e r eﬁ x e di nb u ﬀered formol and stained with hema-
toxylin and eosin (H&E). Immunohistochemistry examina-
tion of endothelium was performed with monoclonal CD34
antibodies (Clone: Qbend 10; Bio Genex, USA; dilution:
1/160) [22], anti-eNOS antibody (Santa Cruz, USA, dilution
1/100). In all cases, the absence of an endothelial cell layer
was observed by H&E, anti-CD-34, and anti-eNOS staining.
nNOS examination was performed with rabbit anti-
nNOS antibody (BD Bioscience Pharmingen; dilution:
1:100) [9]. The positive control for VSMC presence was
performed with anti-α actin antibodies (Sigma Chemical
Company, USA) [23].
The anti-nNOS antibody-stained area was calculated
using a light microscope connected to a video camera and
an informatics system (Image J 1.43μ, MD, USA) calibrated
to correspond to an equivalent μm2 value (1μm2 = 18.400
px), and the anti-nNOS-stained area/total area ratio was
calculated.
2.7. Determination of Oxidative State. To evaluate the oxi-
dative state protein carbonyl content, conjugated diene
(CD) (the primary product of lipid peroxidation), the
reduced/oxidized glutathione (GSH/GSSG) ratio, and thio-
barbituric acid (TBA) reactive substances (TBARS) were
determined.
Rings were homogenized in ice-cold Tris-KCl buﬀer
(0.15M, pH 7.4), precipitated by trichloroacetic acid (TCA:
20%), and centrifuged. The pellet was incubated with 2,4-
dinitrophenylhydrazine (DNPH: 0.002g/mL), washed with
anethanol-ethylacetatemixture,centrifuged,andredissolved
with guanidine HCl/dithiothreitol. Protein carbonyl con-
tents were read spectrophotometrically at 370nm [24]a n d
expressed as pmol/mg protein.
CD was determined spectrophotometrically at 233nm
using a chloroform-methanol mixture [25]a n dw a sc o r r e -
lated with mg of phosphates.
Glutathione was determined by a spectrophotometric
method [26]. To calculate total glutathione, fractions were
homogenized in phosphate buﬀer plus EDTA 6.3mM
(pH 7.4), mixed with TCA 10%, and centrifuged. The
supernatant was incubated with NADPH 0.3mM, DTNB
6mM, and glutathione reductase 0.077U (10μL). To cal-
culate GSH, 20μL of the supernatant was incubated for
15min with DTNB 6mM (0.1mL). GSSG was calculated
by subtracting GSH from the total glutathione. Absorbance
was read spectrophotometrically at 412nm and correlated
with protein contents, and then the GSSG/GSH ratio was
calculated.
Lipid peroxidation was evaluated in SV fractions homog-
enized in detergent-free buﬀer by measurement of malon-
dialdehyde contents [27]. The absorbance was read spec-
trophotometrically at 535nm. The results were expressed as
μmol TBARS/mg of protein, as determined by the Lowry’s
method.
2.8. Data Analysis. Data were expressed as mean ± standard
error (SE).
To calculate pEC50 for each CDRC, the sigmoid equation
of the curve ﬁtting program “Graph-Pad” Prism 3.0 was
used. Paired or nonpaired Student’s t-test and ANOVA with
Newman-Keuls tests were used when appropriate. Results
were considered to be signiﬁcant when P<0.05.
3. Results
3.1. Reactivity to Ang II and NE. Figure 1 shows the vasocon-
tractileresponsetoAngII(Figure 1(a))andNE(Figure 1(b))
onSVringswithoutendotheliumandtheeﬀectofDPIinthis
response.
Ang II (10−9–10−5 M) produced a dose-dependent con-
tractioninbothNTandHTrings(Figure 1(a));however,HT
showed higher Ang II Rmax values (Table 2). A curve ﬁtness
analysis showed no diﬀerence in potency (pEC50)b e t w e e n
NTandHT(−6.5±0.2;n = 7v ersus−6.6±0.1;n = 6,resp.).
InHT,DPIdecreasedtheAngIIdose-dependentcontraction
(Figure 1(a))a n dRmax (Table 2), however, this agent did not
modify the Ang II response in NT. Tempol did not modify
the Ang II Rmax in HT or NT (Table 2).
Similar to Ang II, NE (10−9–10−5 M) produced a dose-
dependent contraction in both NT and HT (Figure 1(b)).
The NE Rmax was higher in HT (Table 2). No diﬀerence
in the NE pEC50 values between NT and HT was found
(−7.6 ± 0.6; n = 6v e r s u s−7.1 ± 0.1; n = 6). In HT, DPI
decreased the NE dose-dependent contraction (Figure 1(a))
and Rmax (Table 2), however, this agent did not modify the
NE response in NT. Tempol did not modify the NE Rmax in
HT or NT (Table 2).
In HT, L-NAME 10−4 M did not modify the Ang II Rmax,
however, it increased the Ang II reactivity in NT (Table 2). L-
NAME did not modify the NE Rmax in HT, but it did increase
the NE reactivity in NT (Table 2). Either Ang II or NE L-
NAME modiﬁed the pEC50.
In contrast to Ang II and NE, the response to KCl
100mM was similar in HT (1115.9 ± 141.7mg;n = 22) and
NT (1056.7 ±193.8mg;n = 10).
3.2. NO Release. Nitrite contents were present in both NT
and HT (1066.1±86.3pmol/mg; n = 11 versus 487.8±51.6;
n = 23; P<0.01), despite the endothelial absence. Moreover,4 International Journal of Hypertension
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Figure 1: Cumulative dose-response curves (CDRC) to agonists in SV rings. (a) CDRC to Angiotensin II (Ang II) in HT (black) and NT
(white) patients in the absence (squares) or presence (circles) of DPI. ∗∗∗P<0.001 HT versus NT. ff: P<0.03 HT versus HT+DPI; fff:
P<0.001 HT versus HT+DPI. +++P<0.001 HT versus NT+DPI. (b) CDRC to norepinephrine (NE) in HT (black) and NT (white) patients
in the absence (squares) or presence (circles) of DPI. ∗∗∗P<0.001 HT versus NT. ff: P<0.03 HT versus HT plus DPI; fff: P<0.001
HT versus HT plus DPI. +++P<0.001 HT versus NT plus DPI. Data are expressed as mean ± standard error. The number of rings is given in
parentheses.
Table 2: Maximal contractile response (Rmax) to Ang II and NE in SV rings.
Ang II Rmax (mg) NE Rmax (mg)
NT HT NT HT
Krebs 581±169 (7)+++ 1193 ±302 (7) 349±132 (6)+++ 951 ±76 (6)
DPI 10−5 M 520 ±163 (6) 680 ±93 (6)∗∗∗ 314 ±76 (6) 434 ±31 (6)∗∗∗
Tempol 10−4 M 580 ±97 (6) 1195 ±289 (7) 332 ±20 (7) 880 ±37 (7)
L-NAME
10−4 M 1380 ±215 (6)∗ 1195 ±289 (7) 947 ±39 (6)∗∗ 955 ±55 (7)
∗P<0.05 versus Krebs; ∗∗P<0.01 versus Krebs, ∗∗∗P<0.001 versus Krebs; +++P<0.001 HT versus NT. The numbers of experiments are given in
parenthesis.
rubbedmaneuversdidnotbluntthenitritecontentsineither
NT (Δ:5± 13%, n = 8; P: NS) or HT (Δ:6± 12%, n = 10;
P:N S ) .
Figure 2 shows the eﬀect of L-NAME on nitrite contents.
L-NAME signiﬁcantly decreased nitrites in all cases. No
diﬀerences between NT and HT in the presence of L-
NAME were found (Figure 2,b l a c kb a r s ) .L - N A M Ep l u s
L-arginine did not modify the nitrite contents in HT (Δ:
11.9±4.2pmol/mg; n = 10) and NT (Δ:1 5 .4±5.2pmol/mg;
n = 6).
Similarly to L-NAME, S-methyl-L-thiocitrulline (nNOS
inhibitor) inhibited nitrites (53.6 ± 6.8%; n = 8; P<0.01
in HT). To test whether nitrite release was mediated by
nNOS (a Ca2+/calmodulin dependent enzyme), nitrites were
measured in the absence of Ca2+.C a 2+-free media decreased
the nitrite contents in NT (Δ: 881.6 ± 37.2pmol/mg; n = 7;
P<0.001) and in HT (Δ: 252.4 ± 43.1pmol/mg; n = 6;
P<0.01). In any case, aminoguanidine did not modify the
nitrite content in NT (Δ:5 4 .2±77.4pmol/mg; n = 7; P:N S )
and in HT (Δ:4 .1 ±53.8pmol/mg; n = 10; P:N S ) .
In HT, an increase of nitrites was observed with DPI
(1024.7 ± 45.4pmol/mg; n = 7; P<0.001) and tempol
(1071.2 ± 77.8pmol/mg; n = 16; P<0.001). In NT, these
agents did not modify the nitrite contents.
Figure 3 shows typical recorders of direct measurements
of NO in basal conditions and the eﬀect of tempol in NT (a)
and HT (b). NT showed higher NO values than HT (48.8 ±
4.7n A ;n = 6v e r s u s1 7 .2 ± 0.8; n = 7; P<0.001). In HT,
tempol 10−4 M increased NO release (42.5 ± 2.7nA;n = 7;
P<0.001). In NT, tempol did not increase the NO contentsInternational Journal of Hypertension 5
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Figure 2: Eﬀect of L-NAME on nitrite contents of NT and HT SV
rings.Whitebars:Krebs.Blackbars:L-NAME10−4 M. ∗∗∗P<0.001
HTversusNT. ++P<0.01HTversusHTplusL-NAME. +++P<0.01
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(49.6±3.6 nA; n = 6; P: NS). Only in HT, DPI increased NO
release (Δ:2 4 .5 ±1.8nA;n = 7; P<0.001).
3.3. Presence of nNOS and eNOS by Immunohistochemistry.
Because NO was present in SV rings without endothelium
andbasedonpreviousﬁndingsfromourlaboratoryinwhich
we demonstrated the nNOS presence in VSMC of IMA rings
[9], immunohistochemistry for nNOS was performed in SV.
In both NT and HT, the anti-nNOS antibody speciﬁcally
stained VSMC (Figure 4). The anti-nNOS-stained area was
higher in NT than HT (26 ± 3.2% of the wall area; n = 7
versus 10 ±0.6; n = 7, resp.; P<0.001). No immunoreactive
product was observed when samples were prepared without
the primary antibody.
In both NT and HT no staining with the anti-eNOS
antibody was observed in the wall of SV rings.
3.4. Determination of Oxidative State. T h el e v e l so fp r o t e i n
carbonyl groups were higher in HT than in NT (21.7 ±
4.4pmol/mg protein; n = 5v e r s us3 .9±0.8; n = 4; P<0.05).
Determinations of CD showed higher values in HT than
in NT (0.26 ± 0.012μL/mg phosphates; n = 6v e r s u s0 .17 ±
0.01; n = 6; P<0.05).
The levels of GSSG were higher in HT than in NT (40.3±
16.3μmol/mg protein; n = 7v e r s u s4 .5 ± 1.8; n = 7; P<
0.05). In addition, HT had elevated GSSG/GSH compared to
NT (21.9 ±8.6; n = 6v e r s u s3 .1 ±1.4; n = 7; P<0.05).
Finally, TBARS levels were higher in HT than in NT
(2.2 ± 0.6nmol/mg protein; n = 6v e r s u s0 .1 ± 0.01; n = 8;
P<0.01).
4. Discussion
We studied the contractility response to exogenous agonists
in SV rings with endothelial dysfunction and the role of the
oxidative stress on this response. Few studies have evaluated
thevascularreactivity,ortheimpactofarterialhypertension,
in SV. The SV is the vessel most commonly used for CABGS.
However, the patency of this graft is controversial. Lytle et
al. [28] have indicated that after 5 years of CABGS, the
graft patency of SV exceeded that of IMA. Souza et al.
[29] have suggested that SV provides high graft patency.
However, Dashwood has indicated that the patency rate is
poor, with a high proportion of patients requiring further
surgery [30]. The mechanisms involved in the patency of SV
are unclear. Some factors implicated are aging [31], serum
cholesterol, diabetes, harvesting technique, or endothelial
integrity. Ca++-protein kinase C-pathways are implicated
in the reactivity of SV grafts [32]. In the present work,
we found a hyperreactivity to both Ang II and NE in
SV from HT patients, which was reverted by antioxidant
agents. In this sense, hyperreactivity to vasoconstrictors has
previously been observed in DOCA-salt hypertensive rats.
Xu et al. [33] have observed increased reactivity to NE
in mesenteric veins, and Li et al. [14]h a v er e p o r t e da
hyperreactivity to endothelin-1 in the vena cava, which was
related to the presence of oxidative stress. In human SV,
hypertensionstimulatesendothelin-1release,whichnotonly
aﬀects vascular reactivity but also increases oxidative stress
[30].
In SV, Sharif et al. have studied the role of oxidative
stress, indicating that N-acetylcysteine does not improve
endothelial-dependent relaxation and VSMC function [34].
However, the same authors found that vitamin C improves
the endothelial-dependent relaxation [17]. In our vessels,
antioxidant agents diminish vascular reactivity, suggesting
that oxidative stress is implicated in the hyperreactivity of
HT.
We also found that the antioxidant agents DPI and tem-
pol increased NO release in SV. However, this NO is present
in rings with endothelial dysfunction. This observation is in
concordance with previous works from our laboratory on
IMA [9, 10], in which we proposed that extraendothelial NO
release is present through nNOS. Here, the extraendothelial
NO presence in SV is supported by the observations that L-
NAME and S-methyl-L-thiocitrulline decrease nitrite levels
and that nNOS is present in VSMC (Figure 4). Another
ﬁnding that support that the source of extraendothelial
NO is through nNOS is the lack of staining with anti-
eNOS antibody. In addition, the nNOS presence in SV has
previously been demonstrated by Webb et al. [35].
Extraendothelial NO release was higher in NT than in
HT. This result is in agreement with previous work in
IMA [9]. To the best of our knowledge, no comparison
of extraendothelial NO release in SV between HT and NT
has been performed. DPI increased the NO contents in HT,
suggesting a higher impact of the oxidative stress in HT
patients. Few studies have been performed examining the
role of oxidative stress in veins. O2
− production has been
demonstrated to be higher in veins than in arteries [36, 37].6 International Journal of Hypertension
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Figure 3: Typical experiment of direct measurement of NO in SV rings with endothelial dysfunction of one NT (upper) and one HT patient
(lower) and the eﬀect of tempol 10−4 M( a r r o w s ) .
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Figure 4: Microphotography (40x) of neuronal nitric oxide synthase (nNOS) immunohistochemistry of a transverse section of SV rings
from one NT (a) and one HT patient (b). The ABC peroxidase method was used to generate the brown stain at the sites of primary antibody
binding.
InhumanSVrings,Marli` ereetal.haveobservedthat5-series
F2-isoprostanes(compoundsproducedbythenonenzymatic
peroxidation of arachidonic acid) do not have vasomotor
eﬀects [38], and Antoniades et al. have shown that folic acid
has beneﬁcial eﬀects on O2
− production [19].
O2
− has been demonstrated not only to be a NO-
scavenger and a vasoconstrictor but also to produce direct
vascular damage. In this sense, Shi et al. [36]h a v eo b s e r v e d
that biological changes in SV grafts are characterized
by oxidative stress resulting from higher O2
− production
and lower superoxide dimutase activity. In our work, the
increased oxidative damage in hypertension is supported by
the observation that the levels of protein carbonyl groups,
CD, GSSG, GSSG/GSH; and TBARS are increased in HT
rings.
The present work demonstrates that extraendothelial
NO counter-regulates contractility in SV used for CABGS.
However, this NO action could be altered in hypertensive
situations, even if there were no other associated risk factors.
We suggest two mechanisms (1) increased oxidative stress
and (2) a decreased ability of nNOS to produce NO. Further
studies should be performed to evaluate the implications of
these results in SV graft patency rates.
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